Interaction between SNP genotype and efficacy of anastrozole and exemestane in early‐stage breast cancer

Clinical Pharmacology & TherapeuticsCairns J, Kalari KR, Ingle JN, et al. | July 01, 2021

Advertisement

This study sought to evaluate genetic factors that could differentiate between the efficacy of adjuvant anastrozole and exemestane by examining single-nucleotide polymorphism (SNP)-treatment interaction in 4,465 patients. A group of SNPs were observed to be differentially correlated between anastrozole and exemestane regarding outcomes. These studies distinguished SNPs that differentiate the effectiveness of anastrozole and exemestane and they imply additional genetic biomarkers for possible use in selecting an AI for a given patient.

Read the full article on Clinical Pharmacology & Therapeutics

Advertisement